



Clearbridge Health Limited
37 Jalan Pemimpin #08-05 Mapex Singapore 577177
TEL 65 6251 0136 FAX 65 6251 0132
clearbridgehealth.com

Clearbridge Health to be exclusive distributor for MILS International in 11 countries

- *To market diagnostic tests using MILS's proprietary urinary metabolites GCMS analysis method, which provides insights into state of personal health and wellness.*
- *Countries include Singapore, India, Indonesia, Malaysia, the Philippines, Korea, Taiwan, Thailand, Vietnam, Australia and Hong Kong.*

SINGAPORE – 23 January 2018 – Clearbridge Health Limited (“Clearbridge” or the “Company” and together with its subsidiaries, the “Group”) (明策集团), a newly listed healthcare company with a focus on the delivery of precision medicine in Asia, has entered into a business collaboration with MILS International (“MILS”) for the exclusive distribution of MILS’s diagnostic tests in 11 countries.

The two-year collaboration will allow Clearbridge to distribute MILS’s full range of tests in Singapore, India, Indonesia, Malaysia, the Philippines, Korea, Taiwan, Thailand, Vietnam, Australia and Hong Kong.

Headquartered in Kanazawa, Japan, MILS is an institution of research and medical examination established in 1997 with the main purpose of diagnosing metabolic diseases in the early stages. It was the first to apply human body fluid metabolites analysis by Gas Chromatography–Mass Spectrometry (“GCMS”). By processing urine samples, MILS’s laboratory can provide reports to guide individuals to start taking preventive health measures and address disorders that can result in early mortality or lifelong disability. Its tests include screening for “Inborn Errors of Metabolism” (“IEM”) and also assessing the healthy functioning of glucose metabolism.

Mr Jeremy Yee (余斌), Executive Director and Chief Executive Officer of Clearbridge, said: *“IEM tests currently available in the market require blood to be drawn from the patient and can only detect up to 40 metabolic disorders. We are thrilled to have the exclusive rights to distribute MILS’s game changing product to the markets covered by our collaboration. Not only is the MILS test non-invasive as it uses urine samples, it can also detect more than 150 metabolic disorders.*

This partnership with MILS is in line with our strategy to take advantage of the best-in-class technologies through collaborations with different third party partner institutions and technology companies to expand our product offering and to gain access to cutting edge research and development.”

Dr Taichiro Ikeda, President of MILS, commented: *“The signing of this business collaboration agreement signifies Clearbridge’s intention to lay a solid foundation for market expansion of metabolomics in Asia. We will also jointly utilise MILS’s technology platform and further explore other synergistic technologies to extend our service offerings in the areas of metabolomics that cater to the Asia-Pacific region.”*



Clearbridge Health Limited
37 Jalan Pemimpin #08-05 Mapex Singapore 577177
TEL 65 6251 0136 FAX 65 6251 0132
clearbridgehealth.com

This partnership comes hot on the heels of Clearbridge's initial public offering on 18 December 2017 and its acquisition of a majority stake in Marzan Health Care Inc., a comprehensive ambulatory medical centre in the Philippines, on 17 January 2018.

Mr Yee added: *"To deliver value to shareholders, our priority is to expand the scale – that is geographical coverage, and the scope of products and services that Clearbridge currently has. With this in mind, we have been pursuing suitable partnerships since the company was established in 2010. To accomplish our mission to be a world-class healthcare company with a focus on the delivery of precision medicine services, we will continue to seek opportunities that fit our corporate goals. We are excited about what lies ahead for the Group and we look forward to updating the market as our plans come into fruition."*

-- END --

About Clearbridge Health Limited

Clearbridge Health Limited is a healthcare company with a focus on the delivery of precision medicine in Asia. Its business comprises laboratory testing services, medical clinics/centres and strategic equity participation in complementary precision medical technology companies. Through the delivery of precision medicine in Asia, it seeks to empower clinicians and healthcare professionals to make more reliable and accurate diagnoses, provide insights to disease management, and tailor personalised prevention and timely treatment programmes for patients.

For more information, please visit us at www.clearbridgehealth.com.

About MILS International

MILS (Matsumoto Institute of Life Science) was founded by Isamu Matsumoto, Emeritus Professor of Kanazawa Medical University in 1997, with the purpose of diagnosing metabolic diseases at an early stage. It was the first to apply GCMS technology to analyse body fluids for metabolic disorder screening and diagnosis in Asia. Leveraging more than twenty years of experience and a comprehensive database of metabolic profiles, MILS is amongst the leaders in the field of metabolomics in Asia. MILS's research and development focus is in the areas of health-screening, diabetes mellitus and evaluation of new drugs.

Issued by and on behalf of Clearbridge Health Limited

August Consulting

Tel: +65 6733 8873

Silvia Heng, silviaheng@august.com.sg

Wrisney Tan, wrisneytan@august.com.sg

Zavier Ong, zavierong@august.com.sg



Clearbridge Health Limited

37 Jalan Pemimpin #08-05 Mapex Singapore 577177
TEL 65 6251 0136 FAX 65 6251 0132
clearbridgehealth.com

This press release has been prepared by the Company and its contents have been reviewed by the Company's sponsor, United Overseas Bank Limited (the "Sponsor"), for compliance with the relevant rules of the Singapore Exchange Securities Trading Limited (the "SGX-ST").

The Sponsor has not independently verified the contents of this press release. This press release has not been examined or approved by the SGX-ST and the SGX-ST assumes no responsibility for the contents of this press release, including the correctness of any of the statements or opinions made or reports contained in this press release.

The contact person for the Sponsor is Mr Chia Beng Kwan, Senior Director, Equity Capital Markets, who can be contacted at 80 Raffles Place, #03-03 UOB Plaza 1, Singapore 048624, Telephone: +65 6533 9898.